Dilated Cardiomyopathy Pipeline Review, H2 2018 - Therapeutic Assessment of 8 Companies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Dilated Cardiomyopathy - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Dilated Cardiomyopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Dilated Cardiomyopathy - Overview Dilated Cardiomyopathy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Dilated Cardiomyopathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Dilated Cardiomyopathy - Companies Involved in Therapeutics Development Array BioPharma Inc C&C BioPharma LLC Capricor Therapeutics Inc Celixir Ltd Hemostemix Inc Kasiak Research Pvt Ltd MyoKardia Inc Sanofi
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rz4x3x/dilated?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006048/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 05:08 PM/DISC: 09/26/2018 05:08 PM